Reuters -- Roche beat forecasts with a 10 percent rise in third-quarter sales, helped by demand for Tamiflu due to the H1N1 swine flu pandemic, and the Swiss group now sees higher drug revenues for the full year.
Reuters -- Roche beat forecasts with a 10 percent rise in third-quarter sales, helped by demand for Tamiflu due to the H1N1 swine flu pandemic, and the Swiss group now sees higher drug revenues for the full year.
